Who are Isauvuconazole group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eraxis, Mycamine, Cancidas, PRA, Antifungal treatment, anidulafungin and voriconazole.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/isauvuconazole-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Isauvuconazole group — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Isauvuconazole group (isauvuconazole-group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Echinocandin. Area: Other.

marketed Echinocandin β-(1,3)-D-glucan synthase Other Live · refreshed every 30 min

Target snapshot

Isauvuconazole group (isauvuconazole-group) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Isauvuconazole group TARGET	isauvuconazole-group	Pfizer	marketed	Echinocandin	β-(1,3)-D-glucan synthase	Not yet launched
Eraxis	ANIDULAFUNGIN	Vicuron Holdings	marketed	Echinocandin Antifungal [EPC]		2006-01-01
Mycamine	MICAFUNGIN	Teva Pharms Usa Inc	marketed	Echinocandin Antifungal	ATP-binding cassette sub-family G member 2	2005-01-01
Cancidas	CASPOFUNGIN	Merck & Co.	marketed	Echinocandin Antifungal	ATP-binding cassette sub-family G member 2	2001-01-01
PRA	PRA	Scynexis, Inc.	marketed	Echinocandin antifungal	β-1,3-glucan synthase (FKS)
Antifungal treatment	Antifungal treatment	Hospices Civils de Lyon	marketed	Antifungal agent (class varies by specific drug: azole, polyene, echinocandin, or other)
anidulafungin and voriconazole	anidulafungin and voriconazole	Pfizer	marketed	Echinocandin and triazole antifungal combination	β-1,3-glucan synthase (anidulafungin); fungal CYP51/lanosterol 14α-demethylase (voriconazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Echinocandin class)

Merck Sharp & Dohme LLC · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Isauvuconazole group — Competitive Intelligence Brief. https://druglandscape.com/ci/isauvuconazole-group. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing